PERSEPHONE: a randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC)
Earl, H Hiller, L Vallier, L Loi, S Howe, D Higgins, H McAdam, K Hughes-Davies, L Harnett, A Ah-See, L
Earl, H
Hiller, L
Vallier, L
Loi, S
Howe, D
Higgins, H
McAdam, K
Hughes-Davies, L
Harnett, A
Ah-See, L
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Earl H, Hiller L, Vallier A, Loi S, Howe D, Higgins H, et al. PERSEPHONE: a randomised phase 3 non-inferiority trial of 6 versus 12 months (m) of adjuvant trastuzumab in patients with HER2 positive (+) early breast cancer (EBC). Br J Cancer. 2018;119(11):43.